Companion Diagnostic Testing for Non-Small Cell Lung Cancer

Companion Diagnostic Testing for Non-Small Cell Lung Cancer

By (author) 

List price: US$6.00

Currently unavailable

We can notify you when this item is back in stock

Add to wishlist

AbeBooks may have this title (opens in new window).

Try AbeBooks

Description

Lung cancer is a malignancy of epidemic proportions. In the United States, it is estimated that there will be more than 228,000 new cases of lunch cancer each year, with 40% of those presenting with Stage IV metastatic disease. Non-small cell lung cancers (NSCLC) make up approximately 70% of all lung cancers diagnosed. Ongoing advancements in medicine are raising the bar in oncology management, including NSCLCs. Data show that patients respond differently to the same drug. By identifying a sub-group of patients most likely to benefit from a specific drug therapy, patients can be confident that their treatment will provide optimal responses. A companion diagnostic enables personalized healthcare. It is used to predict which patients are most likely to benefit from a particular therapy and/or how best to administer a therapy to an individual. This 6 panel pocket card provides at-a-glance information about companion diagnostic testing for non-small cell lung cancers. The card concisely summarizes: epidemiology; histology; etiology and risk factors; evaluation and staging; treatment overview; personalized treatment; companion testing; and implications.
The content is excerpted from Dr. Gary Lyman's Oxford American Handbook of Oncology.
show more

Product details

  • Cards | 2 pages
  • 167.6 x 242.9 x 19mm
  • Oxford, United Kingdom
  • English
  • 0199388644
  • 9780199388646

About Gary H. Lyman

Professor of Medicine and Director of Health Services and Outcomes, Division of Medical Oncology, Duke University Medical Center
show more

Table of contents

1. Lung Cancer: General Overview ; 2. Lung Cancer: Histology ; 3. Etiology and Risk Factors ; 4. Evaluation and Staging ; 5. Treatment Overview ; 6. Personalized Treatment ; 7. Companion Testing ; 8. Implications ; 9. Conclusion
show more